NOTCH1 and glioblastoma: Within this context, administration of MK0752 as a single agent resulted in a stable disease in glioblastoma patients.59 Since GSIs have several side effects including gastrointestinal toxicities and skin disorders, and target other pathways in addition to Notch signaling,60 specific Notch1 inhibitors are of particular interest.